Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.

ABSTRACT: We live in an era of genomic medicine. The past five years brought about many significant achievements in the field of cancer genetics, driven by rapidly evolving technologies and plummeting costs of next-generation sequencing (NGS). The official completion of the Cancer Genome Project in 2014 led many to envision the clinical implementation of cancer genomic data as the next logical step in cancer therapy. Stemming from this vision, the term 'precision oncology' was coined to illustrate the novelty of this individualised approach. The basic assumption of precision oncology is that molecular markers detected by NGS will predict response to targeted therapies independently from tumour histology. However, along with a ubiquitous availability of NGS, the complexity and heterogeneity at the in

SUBMITTER: Horak P 

PROVIDER: S-EPMC5133384 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature